secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0000950170-25-097881
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026
--------------------------------------------------------------------------------

- Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.
- Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).
- ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.
- Restructuring and program cuts expected to extend cash runway into Q4 2026.
- ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/acet-20250722.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-097881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer